Saturday 17 October 2026 Export ELTX’s income statement to Excel — free account

Elicio Therapeutics, Inc.

In the quarter to June 2026, EPS grew 34.9%, free cash flow grew 8.77% and total debt rose 2.12%, each against the same quarter a year earlier.

1.56 0.22 −12.36%

Follow ELTX

Alert me

Market cap: $48.2M
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 6/9
Altman Z: 0.10
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 48.22

Revenue 28.90

Net Income (37.84)

Free Cash Flow (37.69)

Net Debt (13.94)

Current Ratio 2.77

Debt/Equity 1.20

P/E ratio 0.00

Fwd P/E 0.00

P/S ratio 1.04

P/B ratio 3.78

Past 5Y EPS Growth —

This Y EPS Growth 27.07%

Next Y EPS Growth 10.13%

Next Y revenue growth (91.88%)

Next 5Y EPS Growth 22.95%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 24.74%

10-year low 10-year high

P/B against its own 10 years 50.83%

10-year low 10-year high

EV/Sales against its own 10 years 9.40%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	14	19	19	23
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	16	21	19	25

	2023	2024	2025	Q'26
Payables	4	1	1	1
ST’ Debt	—	—	—	—
Other	1	1	—	—
	10	12	8	9

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	15.66%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(43.17%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	—	—	—	—
’21	0	1	1	26	28
’20	1	1	1	0	3
’19	—	—	—	1	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(8)	—	—	—
’25	(10)	(9)	(11)	(7)	(37)
’24	(12)	(9)	(7)	(9)	(37)
’23	(8)	(9)	(5)	(10)	(33)
’22	(16)	6	(5)	(7)	(22)
’21	(13)	(11)	(15)	(14)	(53)
’20	(9)	(13)	(22)	21	(23)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(8)	—	—	—
’25	(10)	(9)	(11)	(7)	(37)
’24	(12)	(9)	(7)	(9)	(37)
’23	(8)	(9)	(5)	(10)	(33)
’22	(16)	6	(5)	(7)	(23)
’21	(13)	(11)	(15)	(14)	(53)
’20	(9)	(13)	(22)	21	(23)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.65)	(0.43)	—	—	—
’25	(0.87)	(0.66)	(0.60)	(0.49)	(2.58)
’24	(1.15)	(0.64)	(1.39)	(1.02)	(4.25)
’23	(24.77)	(2.61)	(1.27)	(3.77)	(6.96)
’22	(4.80)	(23.17)	(22.64)	(2.10)	(89.27)
’21	(15.60)	(5.80)	(5.30)	5.80	(19.30)
’20	(9.14)	(14.01)	(11.90)	(19.00)	(54.30)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	22.80	7.40	4.60	2.96	4.60	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	263.00	31.20	24.39	11.45	12.62
People
People	Employees	—	—	—	—	53	71	12	32	32	33
	Revenue/emp, $m	—	—	0.00	0.00	0.05	0.40	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	4	1	3	28	—	—	—	—
	Gross margin, %	—	—	90.62	56.96	58.68	98.47	100.00	—	—	—
	EBT	—	—	(20)	(41)	(80)	(55)	(28)	(35)	(52)	(40)
	EBT margin, %	—	—	(497.02)	(2,734.23)	(2,781.49)	(192.76)	0.00	0.00	0.00	0.00
	Net income	—	0	(20)	(41)	(80)	(55)	(28)	(35)	(52)	(40)
	Depreciation	—	—	0	0	8	3	1	1	1	1
Per share, $
Per share, $	Revenue	—	—	1.37	1.03	1.95	10.02	0.00	0.00	0.00	0.00
	Earnings	—	—	(8.48)	(28.17)	(54.30)	(19.30)	(89.27)	(6.96)	(4.25)	(2.58)
	Cash flow	—	—	(2.72)	(17.03)	(15.50)	(18.64)	(70.19)	(6.47)	(3.04)	(2.41)
	Capex	—	—	0.00	(0.17)	(0.03)	(0.14)	(2.07)	(0.01)	(0.01)	0.00
	Free cash flow	—	—	(2.72)	(17.20)	(15.53)	(18.77)	(72.26)	(6.47)	(3.04)	(2.41)
	Book value	—	—	6.42	(12.88)	(61.27)	28.86	28.21	2.25	(0.93)	0.11
	Shares, m	—	—	3	1	1	3	0	5	12	15
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	—	—	—
	P/S	—	—	89.87	89.87	89.87	2.89	0.10	—	—	—
	P/B	—	—	0.00	0.00	0.00	1.01	0.00	—	—	—
	EV/Sales	—	—	78.16	78.16	78.16	(0.20)	(0.05)	—	—	—
	EV/FCF	—	—	(9.82)	(9.82)	(9.82)	0.11	0.06	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(8)	(25)	(23)	(53)	(22)	(33)	(37)	(37)
	Capex	—	—	—	0	0	0	(1)	0	0	0
	Free cash flow	—	—	(8)	(25)	(23)	(53)	(23)	(33)	(37)	(37)
Balance, $m
Balance, $m	Working capital	—	—	18	(20)	(65)	80	4	7	9	11
	Total debt	—	—	—	11	1	0	0	—	20	9
	Net debt	—	—	(26)	5	(34)	(89)	(8)	(14)	1	(9)
	Shareholders’ equity	—	—	19	(19)	(90)	82	9	11	(11)	2
Returns, %
Returns, %	ROA	—	—	(187.81)	(211.13)	(270.48)	(75.87)	(47.34)	(141.32)	(187.61)	(146.45)
	ROIC	—	—	0.00	0.00	0.00	0.00	(1,153.43)	0.00	0.00	0.00
	ROE	—	—	(15,387.69)	(25,020.31)	146.94	1,220.60	273.36	77.55	(170,157.38)	817.92

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2021 · latest quarter Mar 2022

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CRBU Caribou Biosciences, Inc.	$49.8M	— (loss-making)	— (loss-making)	−43.79% (below 0%: shrinking)	n/m	−33.16% (below 0%: shrinking)	100.00%	(1,690.39%)	Compare
MREO Mereo BioPharma Group plc - Sponsored ADR	$49.3M	— (loss-making)	— (loss-making)	—	n/m	+21.02% (above 0%: growing)	0.00%	0.00%	Compare
HYPD Hyperion DeFi, Inc.	$49.0M	— (loss-making)	3.6×	+2,333.33% (above 0%: growing)	n/m	+86.82% (above 0%: growing)	100.00%	8,668.63%	Compare
HOWL Werewolf Therapeutics, Inc.	$48.5M	— (loss-making)	— (loss-making)	+256.11% (above 0%: growing)	n/m	+146.46% (above 0%: growing)	100.00%	34.09%	Compare
ELTX Elicio Therapeutics, Inc.	$48.2M	— (loss-making)	— (loss-making)	−55.27% (below 0%: shrinking)	n/m	+8.77% (above 0%: growing)	0.00%	0.00%
ACET Adicet Bio, Inc.	$48.1M	— (loss-making)	— (loss-making)	+727.73% (above 0%: growing)	n/m	+24.94% (above 0%: growing)	0.00%	0.00%	Compare
KLRS Kalaris Therapeutics Inc.	$47.8M	— (loss-making)	—	—	n/m	+11.91% (above 0%: growing)	0.00%	0.00%	Compare
IBIO iBio, Inc.	$47.6M	— (loss-making)	— (loss-making)	+100.00% (above 0%: growing)	n/m	−35.33% (below 0%: shrinking)	100.00%	0.00%	Compare
CLNN Clene Inc.	$47.0M	— (loss-making)	— (loss-making)	+233.33% (above 0%: growing)	n/m	+45.43% (above 0%: growing)	60.00%	(5,941.11%)	Compare
Median of peers	$48.3M	—	—	+244.72%	—	+22.98%	80.00%	0.00%

All 614 Biotechnology stocks →

Elicio Therapeutics, Inc. (ELTX) key facts

Elicio Therapeutics, Inc. (ELTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ELTX traded at $1.56, a market capitalization of $48.2 million.
Return on equity was 817.9% and debt-to-equity 1.20.

Source: company filings (standardised) and stockrow calculations.